Overview of China's Market Approval Policy Med Insurance Payment System
Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.
In this whitepaper, hear from Parexel rare disease consultants on the following topics:
- Relevant Policies on Expedited Approval of Rare Disease Drugs
- An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs
Related Insights
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Using Managed Entry Agreements to address JCA-era uncertainties
May 13, 2025
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Related Insights
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Using Managed Entry Agreements to address JCA-era uncertainties
May 13, 2025
Blog
Early Scientific Advice in cost effectiveness markets – how to navigate it and is it worth it?
Jun 14, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022